All In Biotech

Drug Trial Radar · NCT05096364

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Apr 28, 2021

Primary completion

Feb 3, 2023

Study completion Feb 3, 2023

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • AK111/PlaceboBiological

    After loading dose, investigational drug was administered subcutaneously up to 60 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieve Psoriasis Area and Severity Index (PASI) 90 response or higher at week 12Time frame: At week 12

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • AkesoBio Investigative Site 1011

    Bengbu, Anhui, China

  • AkesoBio Investigative Site 1009

    Beijing, Beijing Municipality, China

  • AkesoBio Investigative Site 1016

    Beijing, Beijing Municipality, China

  • AkesoBio Investigative Site 1003

    Guangzhou, Guangdong, China

  • AkesoBio Investigative Site 1007

    Guangzhou, Guangdong, China

  • AkesoBio Investigative Site 1012

    Chengde, Hebei, China

  • AkesoBio Investigative Site 1018

    Harbin, Heilongjiang, China

  • AkesoBio Investigative Site 1008

    Changsha, Hunan, China

  • AkesoBio Investigative Site 1013

    Yancheng, Jiangsu, China

  • AkesoBio Investigative Site 1001

    Shanghai, Shanghai Municipality, China

  • AkesoBio Investigative Site 1010

    Shanghai, Shanghai Municipality, China

  • AkesoBio Investigative Site 1002

    Hanzhou, Zhejiang, China

  • AkesoBio Investigative Site 1006

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.